Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose-Escalation Study of HTX-034 Following Bunionectomy
Sponsor: Heron Therapeutics
Summary
This was a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b evaluated escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 was a dose-expansion phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase 1b, compared with bupivacaine HCl.
Official title: A Phase 1b/2, Randomized, Blinded, Active-Controlled Study of Escalating Doses of HTX-034 for Postoperative Analgesia in Subjects Undergoing Unilateral, First Metatarsal Bunionectomy With Osteotomy and Internal Fixation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2020-05-08
Completion Date
2021-07-15
Last Updated
2026-06-09
Healthy Volunteers
No
Conditions
Interventions
HTX-034 low dose
HTX-034 (bupivacaine/aprepitant/meloxicam) fixed dose: 21.7 mg/4.3 mg/0.6 mg
HTX-034 high dose
HTX-034 (bupivacaine/aprepitant/meloxicam) individualized dose: 30.6 mg/6.1 mg/0.9 mg to 51.5 mg/10.3 mg/1.5 mg
Luer lock applicator
Applicator for instillation
Bupivacaine HCl
Bupivacaine HCl 50 mg
Locations (4)
Arizona Research Center
Phoenix, Arizona, United States
First Surgical Hospital
Bellaire, Texas, United States
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
JBR Clinical Research
Salt Lake City, Utah, United States